- Home
- CALM vs DNLI Comparison
CALM vs DNLI Comparison
Compare CALM & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALM
- DNLI
- Stock Information
- Founded
- CALM 1957
- DNLI 2013
- Country
- CALM United States
- DNLI United States
- Employees
- CALM N/A
- DNLI N/A
- Industry
- CALM Farming/Seeds/Milling
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CALM Consumer Staples
- DNLI Health Care
- Exchange
- CALM Nasdaq
- DNLI Nasdaq
- Market Cap
- CALM 4.5B
- DNLI 4.5B
- IPO Year
- CALM 1996
- DNLI 2017
- Fundamental
- Price
- CALM $90.76
- DNLI $26.49
- Analyst Decision
- CALM Sell
- DNLI Strong Buy
- Analyst Count
- CALM 3
- DNLI 11
- Target Price
- CALM $66.33
- DNLI $38.90
- AVG Volume (30 Days)
- CALM 459.0K
- DNLI 718.4K
- Earning Date
- CALM 01-02-2025
- DNLI 11-06-2024
- Dividend Yield
- CALM 4.51%
- DNLI N/A
- EPS Growth
- CALM N/A
- DNLI N/A
- EPS
- CALM 8.73
- DNLI N/A
- Revenue
- CALM $2,652,970,000.00
- DNLI N/A
- Revenue This Year
- CALM $12.75
- DNLI N/A
- Revenue Next Year
- CALM N/A
- DNLI $283.75
- P/E Ratio
- CALM $10.36
- DNLI N/A
- Revenue Growth
- CALM N/A
- DNLI 204.74
- 52 Week Low
- CALM $45.07
- DNLI $14.56
- 52 Week High
- CALM $95.06
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- CALM 54.79
- DNLI 45.97
- Support Level
- CALM $90.75
- DNLI $26.17
- Resistance Level
- CALM $93.17
- DNLI $33.33
- Average True Range (ATR)
- CALM 2.14
- DNLI 1.47
- MACD
- CALM -0.40
- DNLI 0.02
- Stochastic Oscillator
- CALM 51.71
- DNLI 23.65
About CALM Cal-Maine Foods Inc.
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.